Anti-D Information
Anti-D Immunoglobulin (RhIg) is a sterile solution of human IgG antibodies against the RhD antigen. It is given to RhD-negative women so their immune system never becomes sensitised to RhD-positive fetal red cells, preventing Haemolytic Disease of the Fetus and Newborn (HDFN) in the current and every future pregnancy.
What Anti-D is and why it is needed
Anti-D Immunoglobulin is purified human IgG anti-RhD, manufactured from the plasma of donors who have been deliberately immunised against the RhD antigen. It is a passive immunisation: the antibodies are supplied ready-made, they do not teach the mother's immune system anything, and they clear any RhD-positive red cells from her circulation before her own immune system can mount a memory response.
About 15% of people are RhD-negative. When an RhD-negative mother carries an RhD-positive baby, a small fetomaternal haemorrhage during pregnancy or delivery can push fetal red cells into the maternal circulation. Without Anti-D, roughly 16% of these women will become sensitised: they make permanent anti-D antibodies. Those antibodies cross the placenta in the NEXT pregnancy and destroy the baby's red cells — causing anaemia, hydrops fetalis, kernicterus or stillbirth.
Haemolytic Disease of the Fetus and Newborn (HDFN). Severity ranges from mild neonatal jaundice needing phototherapy to severe anaemia requiring intrauterine transfusion, to fetal death. Because maternal antibodies persist for life, the risk increases with every subsequent RhD-positive pregnancy. Routine Anti-D prophylaxis has cut the incidence of anti-D alloimmunisation by more than 90%.
Indications — when Anti-D must be given
| Situation | Who | Timing | Note |
|---|---|---|---|
| Routine antenatal prophylaxis | Every RhD-negative pregnant woman, whether or not any bleeding has occurred | 28 weeks (single dose) or 28 + 34 weeks (two-dose schedule) | Covers the third-trimester silent fetomaternal haemorrhage. |
| Within 72 hours of delivery | RhD-negative mother of an RhD-positive (or unknown) newborn | As soon as possible, ideally ≤72 hours after birth | Dose adjusted by Kleihauer-Betke / flow-cytometry FMH volume. |
| Miscarriage, threatened or complete | RhD-negative woman, ≥12 weeks gestation (or any gestation with surgical evacuation) | Immediately at presentation | Before 12 weeks a smaller 50–120 mcg dose is acceptable where available. |
| Ectopic pregnancy / molar pregnancy | All RhD-negative women | At diagnosis or after treatment | Trophoblastic tissue expresses RhD. |
| Termination of pregnancy | All RhD-negative women, any gestation | Same day as the procedure | Dose scales with gestational age. |
| Invasive prenatal procedures | Amniocentesis, CVS, fetal blood sampling, external cephalic version, abdominal trauma | Within 72 hours of the event | Repeat dosing every 6 weeks if procedures are repeated. |
| Antepartum haemorrhage | Any bleeding episode in an RhD-negative pregnancy | Within 72 hours of each episode, repeated every 6 weeks if bleeding continues | Do not wait for delivery. |
| Transfusion of RhD-positive blood | RhD-negative girl or woman of childbearing potential wrongly transfused RhD-positive red cells or platelets | Immediately on discovery | ≈20 mcg per mL of RhD-positive red cells; large volumes may need exchange transfusion. |
Dosage and route
| Scenario | Dose | Route | Repeat |
|---|---|---|---|
| Antenatal prophylaxis (28 weeks) | 1500 IU (300 mcg) IM | Intramuscular, deltoid or anterolateral thigh | Single dose; or 500 IU at 28 and 34 weeks in the two-dose schedule |
| Postnatal prophylaxis, standard FMH < 4 mL fetal red cells | 1500 IU (300 mcg) IM | Intramuscular | Once, within 72 hours of birth |
| Large fetomaternal haemorrhage | Add 125 IU per extra 1 mL of fetal red cells above 4 mL | IM (IV formulations where licensed) | Guided by Kleihauer-Betke test at 48–72 hours postpartum |
| First-trimester event (< 12 weeks) | 50–120 mcg (250–600 IU) | Intramuscular | Once |
| Events from 12 weeks onwards | 300 mcg (1500 IU) | Intramuscular | Once per event |
| Wrong-blood-group transfusion | ≈20 mcg (100 IU) per 1 mL of RhD-positive red cells | Divided IM/IV over days | Until the transfused RhD-positive cells are cleared |
Timing schedule through pregnancy
Administration technique
- Check maternal blood group, RhD type and current antibody screen before every dose.
- If anti-D is ALREADY present in the maternal plasma as an immune antibody, Anti-D prophylaxis is useless — refer to obstetric medicine for fetal surveillance.
- Deep intramuscular injection into the deltoid (or anterolateral thigh in small adults). Aspirate before injecting.
- Never mix Anti-D with other drugs or vaccines in the same syringe. It may be given at a different site on the same day as routine vaccines, including live vaccines.
- Observe the patient for 20 minutes afterwards — anaphylaxis is rare but possible in IgA-deficient recipients.
- Record the batch number, dose and date in the antenatal record and give the patient a card.
- A Kleihauer-Betke acid-elution test at 48–72 hours detects under-dosing; flow cytometry is preferred where available.
Common side effects
- Pain, tenderness, redness or a small lump at the injection site (most frequent complaint)
- Low-grade fever, headache, malaise, mild chills
- Transient skin rash or itching
Rare but serious
- Anaphylaxis or anaphylactoid reaction — especially in IgA-deficient patients with anti-IgA antibodies
- Urticaria, arthralgia, myalgia several days after injection
- Very rarely, disseminated intravascular coagulation in patients receiving large IV doses for wrong-blood-group transfusion
Contraindications
- Known hypersensitivity to human immunoglobulin preparations or to any excipient (e.g. glycine, polysorbate 80)
- RhD-positive women and RhD-negative women already alloimmunised to RhD (no benefit)
- Severe thrombocytopenia or coagulopathy — prefer an IV formulation over intramuscular injection
- IgA deficiency with documented anti-IgA antibodies — use an IgA-depleted product or avoid
Storage and cold chain
- Store at 2 °C to 8 °C. DO NOT FREEZE — a frozen vial must be discarded.
- Protect from light in the original carton.
- After reconstitution use immediately; some products allow up to 4 hours at 2–8 °C.
- The cold chain is the single most common cause of Anti-D failure in district-level practice in Bangladesh — verify the vaccine-carrier temperature log before injecting.
FAQ
Sources
- ACOG Practice Bulletin No. 181 — Prevention of Rh D Alloimmunization
- RCOG Green-top Guideline No. 65 — The Management of Rhesus Isoimmunisation in Pregnancy
- WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience
- Bangladesh National Guideline on Maternal & Neonatal Care, DGHS
This is general information and is not a substitute for a doctor’s advice.
Quick dose card
Anti-D in the shop
Rhophylac Anti-D 300 mcg is listed under the Medicine category.
Shop Compatibility ReviewsAdmin-managed entries
8 articlesRoutine antenatal prophylaxis
Every RhD-negative pregnant woman, whether or not any bleeding has occurred. Covers the third-trimester silent fetomaternal haemorrhage.
Within 72 hours of delivery
RhD-negative mother of an RhD-positive (or unknown) newborn. Dose adjusted by Kleihauer-Betke / flow-cytometry FMH volume.
Miscarriage, threatened or complete
RhD-negative woman, ≥12 weeks gestation (or any gestation with surgical evacuation). Before 12 weeks a smaller 50–120 mcg dose is acceptable where available.
Ectopic pregnancy / molar pregnancy
All RhD-negative women. Trophoblastic tissue expresses RhD.
Termination of pregnancy
All RhD-negative women, any gestation. Dose scales with gestational age.
Invasive prenatal procedures
Amniocentesis, CVS, fetal blood sampling, external cephalic version, abdominal trauma. Repeat dosing every 6 weeks if procedures are repeated.
Antepartum haemorrhage
Any bleeding episode in an RhD-negative pregnancy. Do not wait for delivery.
Transfusion of RhD-positive blood
RhD-negative girl or woman of childbearing potential wrongly transfused RhD-positive red cells or platelets. ≈20 mcg per mL of RhD-positive red cells; large volumes may need exchange transfusion.